2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Revvity, Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #419 · Revvity公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | RVTY |
| Company | Revvity, Inc. |
| GICS sector / industry | Health Care (XLV) / Life Sciences Tools & Services |
| S&P 500 rank (by weight) | #419 · 0.03% (Nov 4, 2026) |
| Sector rank | #50 of 60 in Health Care (Nov 4, 2026) |
| Headquarters | Waltham, Massachusetts |
| Founded | May 9, 2023 (heritage: PerkinElmer, 1937) |
| CEO | Dr. Prahlad R. Singh (President and CEO) |
| Employees | ~11,000 (as of December 28, 2025) |
| Market cap | $18.24B (Nov 4, 2026) |
| SEC filings | EDGAR — CIK 0000031791 |
WHAT IT DOES
Revvity, Inc. is a life-sciences and diagnostics company providing instruments, reagents, software and services that help researchers discover new medicines and clinicians detect disease early, headquartered in Waltham, Massachusetts. It was created in 2023 when PerkinElmer's life-sciences and diagnostics business was renamed after the sale of its applied, food and enterprise services.
Its one-line model: sell the tools of discovery and detection — instruments plus the recurring reagents and software that run on them — into research labs and screening programmes. Fiscal 2025 total revenue was $2.86B, with operating income of $356.6M and net income of $241.2M.
The moat is installed instruments and validated assays: once a lab standardises on a platform, switching costs are high and reagent revenue recurs. Growth comes from reagents, software subscriptions and diagnostics expansion, especially newborn and infectious-disease screening.
BUSINESS SEGMENTS
| Life Sciences | Instruments, reagents, informatics, software, subscriptions, detection and imaging technologies enabling research breakthroughs; contract research and laboratory services. Fiscal 2025 revenue $1,431.104M. |
| Diagnostics | Instruments, reagents, assay platforms and software for early detection of genetic disorders, pregnancy and early-childhood screening, and infectious-disease testing. Fiscal 2025 revenue $1,424.947M. |
HISTORY
| Year | Milestone |
|---|---|
| 1937 | PerkinElmer is founded (April 19, 1937) by Richard Perkin and Charles Elmer. |
| 2021 | PerkinElmer acquires BioLegend for $5.25B, expanding the life-science franchise. |
| 2022 | PerkinElmer agrees to divest its Applied, Food and Enterprise Services (AFES) businesses to New Mountain Capital for $2.45B total consideration. |
| 2023 | AFES divestiture completes (March 13, 2023); the divested businesses keep the PerkinElmer name. |
| 2023 | The remaining life-sciences and diagnostics business launches as Revvity, Inc.; NYSE ticker changes PKI to RVTY on May 16, 2023. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $2.86B (FY2025 revenue) |
| Operating income | $356.6M (FY2025 operating income) |
| Net income | $241.2M (FY2025 net income) |
| Diluted EPS | $2.07 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Revvity is a small-weight health care constituent: rank #419 by weight at 0.03% as of Nov 4, 2026, and #50 in Health Care. As the renamed, focused successor to PerkinElmer's life-sciences business, it is a direct read on research-tool spending and the growth of early-disease screening.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Revvity, Inc. fiscal 2025 Form 10-K via SEC EDGAR and fiscal 2025 results release (see Financial Snapshot note); headquarters, CEO and history via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 4, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $18.24B (Slickcharts, Nov 4, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | RVTY |
| 公司 | Revvity, Inc.(Revvity) |
| GICS 板塊/行業 | 健康護理(XLV)/生命科學工具及服務 |
| 標普500排名(按權重) | #419 · 0.03%(Nov 4, 2026) |
| 板塊內排名 | 健康護理板塊 #50(共 60 家)(Nov 4, 2026) |
| 總部 | 美國麻薩諸塞州沃爾瑟姆 |
| 成立 | 2023年5月9日(前身 PerkinElmer,1937年) |
| 執行長 | Prahlad R. Singh 博士(總裁兼執行長) |
| 員工 | 約11,000人(截至2025年12月28日) |
| 市值 | $18.24B(Nov 4, 2026) |
| SEC 申報 | EDGAR — CIK 0000031791 |
業務概覽
Revvity, Inc. 是生命科學與診斷公司,提供儀器、試劑、軟件與服務,協助研究人員發現新藥、臨床醫生及早檢測疾病,總部位於麻薩諸塞州沃爾瑟姆。公司於 2023 年創立,當時 PerkinElmer 在出售應用、食品及企業服務後,將餘下的生命科學與診斷業務更名。
其一句話商業模式是:向研究實驗室與篩查計劃銷售發現與檢測工具——儀器加上在其上運行的經常性試劑與軟件。2025 財年總收入 28.56 億美元,營業利潤 3.57 億美元,淨利潤 2.41 億美元。
護城河是已安裝儀器與經驗證的檢測:實驗室一旦標準化某一平台,轉換成本高昂,試劑收入經常性重複。增長來自試劑、軟件訂閱與診斷擴展,特別是新生兒與傳染病篩查。
業務板塊
| 生命科學 | 令研究突破成為可能的儀器、試劑、資訊學、軟件、訂閱、檢測與成像技術;合約研究與實驗室服務。2025 財年收入 14.31104 億美元。 |
| 診斷 | 用於早期檢測遺傳疾病、懷孕與幼兒篩查及傳染病檢測的儀器、試劑、檢測平台與軟件。2025 財年收入 14.24947 億美元。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1937 | PerkinElmer 由 Richard Perkin 與 Charles Elmer 創立(1937 年 4 月 19 日)。 |
| 2021 | PerkinElmer 以 52.5 億美元收購 BioLegend,擴展生命科學業務。 |
| 2022 | PerkinElmer 同意以 24.5 億美元總代價向 New Mountain Capital 剝離應用、食品及企業服務(AFES)業務。 |
| 2023 | AFES 剝離完成(2023 年 3 月 13 日);被剝離業務保留 PerkinElmer 名稱。 |
| 2023 | 餘下的生命科學與診斷業務以 Revvity, Inc. 推出;紐約證券交易所股票代號於 2023 年 5 月 16 日由 PKI 改為 RVTY。 |
競爭地位
財務快照
| 總收入 | 28.56 億美元(2025 財年收入) |
| 營業利潤 | 3.57 億美元(2025 財年營業利潤) |
| 淨利潤 | 2.41 億美元(2025 財年淨利潤) |
| 稀釋 EPS | 2.07 美元(2025 財年稀釋 EPS) |
主要風險
對標普500的重要性
Revvity 是權重較小的健康護理成分股:按權重排名 #419,權重 0.03%(以 2026 年 11 月 4 日為準),健康護理板塊內排名 #50。作為 PerkinElmer 生命科學業務更名後的專注承繼者,它是研究工具開支與早期疾病篩查增長的直接指標。
來源與方法
| 財務、板塊、總部 | Revvity, Inc. 2025 財年 Form 10-K 數據,經 SEC EDGAR 及 2025 財年業績公佈(見財務快照附註);總部、執行長與歷史經 Form 10-K 及維基百科公司資料 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 4, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $18.24B(Slickcharts,Nov 4, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-04 02:22 · updated 2026-11-15 00:00 · rev 6